Additionally, Myojin et al. found that A2AR inhibition could increase the anti-tumor efficacy of anti-PD1 treatment in HCC mouse models, which also indicated the anti-cancer effects of A2AR blockage (Myojin et al., 2024). The gene discussed is ADORA2A; the disease is hepatocellular carcinoma.